Recent News
Sep 20, 2022

- STS101 demonstrated a favorable safety and tolerability profile, consistent with clinical experience to date - Over 8,000 migraine attacks treated with more than 10,000 doses of STS101; of...

Sep 6, 2022

South San Francisco, CA, September 6, 2022 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...

Stock Info